NCT03486340 (CATCH) is a NA clinical trial of Cardiologic assessment in Solid Carcinoma, sponsored by Vejle Hospital.

Who is sponsoring NCT03486340?

NCT03486340 is sponsored by Vejle Hospital.

What drugs are being tested in NCT03486340?

Interventions in NCT03486340: Cardiologic assessment.

What condition does NCT03486340 study?

NCT03486340 studies Solid Carcinoma, 5-Fluorouracil Toxicity, Cardiotoxicity, Chemotherapeutic Toxicity, Acute Coronary Syndrome, Coronary Artery Calcification, Chest Pain.

Is NCT03486340 still recruiting?

NCT03486340 is currently completed. Last updated 8 July 2024.

Last reviewed 2024-07-08 · How we verify

NCT03486340: CATCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Chest Pain in Chemo-treated Cancer Patients

Completed NA Last updated 8 July 2024

What this trial tests

NA trial testing Cardiologic assessment in Solid Carcinoma in 218 participants. Completed in 7 June 2024.

Timeline

11 April 2018

Primary endpoint
7 June 2024

7 June 2024

Quick facts

Lead sponsor	Vejle Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	218
Start date	11 April 2018
Primary completion	7 June 2024
Estimated completion	7 June 2024
Sites	1 location across Denmark

Drugs / interventions tested

Cardiologic assessment

Conditions studied

Solid Carcinoma — all drugs for Solid Carcinoma →
5-Fluorouracil Toxicity — all drugs for 5-Fluorouracil Toxicity →
Cardiotoxicity — all drugs for Cardiotoxicity →
Chemotherapeutic Toxicity — all drugs for Chemotherapeutic Toxicity →

Sponsor

Vejle Hospital

Who can join

18 and older, any sex, with Solid Carcinoma or 5-Fluorouracil Toxicity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment prior to the 5-FU treatment. The investigators hypothesize that aggressive management of ischemic risk factors in asymptomatic patients will reduce the number of hospitalisations and investigations for acute coronary syndrome during and after 5-FU treatment and that patients with high coronary artery calcium scores are more likely to experience chest pain during the treatment with 5-FU.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial.
Lyhne JD, Hansen VB, Vestergaard LD, Hosbond SE, et al · · 2025 · cited 1× · PMID 40382663 · DOI 10.1186/s40959-025-00344-3

Verify or expand the search:

Other recruiting trials for Solid Carcinoma

Currently open trials in the same condition.

NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
NCT06894745 — PET [89Zr]DFO-starPEG in Solid Tumors · Phase 1 · recruiting
NCT06751329 — A Study of DM002 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06475937 — A Study of DM001 in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06104488 — A Study of Avutometinib for People With Solid Tumor Cancers · Phase 1 · recruiting

Other Vejle Hospital trials

Trials by the same sponsor.

NCT05776381 — The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp · Phase 2 · not yet recruiting
NCT07281820 — FRAME - Implementation of a PRO Measure to Inform Patient-Centered Survivorship Care in Oncology Outpatient Visits · NA · recruiting
NCT07511881 — Far-UVC and Infections in Long-term Care Facilities · NA · completed
NCT06279143 — The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes · recruiting
NCT06240078 — Impact of COPD on Sexual Health, Loneliness, and Well-being · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03486340 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vejle Hospital
Last refreshed: 8 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03486340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing